About this trial
CAPITAL OFFLOAD-SHOCK will aim to answer if early use of renal replacement therapy, like dialysis, in patients with reduced body fluids causing the heart to be unable to pump enough blood through the body reduces in-hospital death when compared to the current standard of care. The current standard of care is to wait until renal replacement therapy is clinically necessary.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
adult patients >/= 18 years of age admitted to an intensive care unit
Diagnosed clinically with Society for Cardiovascular Angiography and Interventions (SCAI) Class C or D cardiogenic shock
Clinical or hemodynamic evidence of volume overload
Disqualifiers
Patients whose care plan, as determined by the treating clinical team, will not include renal replacement therapy
Decision has already been made by the treating clinical team to initiate renal replacement therapy
Hyperkalemia with serum potassium >/= 6mmol/L at the time of screening
Severe metabolic acidosis with serum bicarbonate </= 12 mmol/L at the time of screening
Trial design
Parallel
Treatments tested in this trial
Immediate renal replacement therapy
DrugRenal replacement therapy started within 6 hours of randomization
Treatment groups
Trial outcomes
Primary outcomes
All cause mortality
Occurrences of death from any cause
Increased serum lactate
Serum lactate greater than 3.5 mmol/L between 6 and 24 hours after randomization
Mechanical circulatory support
New need for, or replacement of, a mechanical circulatory support device.
Resuscitated cardiac arrest
Occurrences of resuscitated cardiac arrest
Secondary outcomes
Continued renal replacement therapy
Renal replacement therapy dependence for participants at discharge from index hospitalization
Length of hospital stay
Number of days spent in hospital
Length of intensive care unit stay
The number of days spent in the intensive care unit during index hospitalization
Major bleeding events
Bleeding events defined as the Bleeding Academic Research Consortium (BARC) type 3 or higher)
Sponsors and contacts
Click on the lead sponsor to view all of their trials.
This trial is not recruiting at the moment. You can still explore other options: